Multi-national Investigator-Initiated Clinical Studies in Cardiovascular, Autoimmune, Metabolic, and Non-Communicable Respiratory Diseases, including Underrepresented Populations (IICS4all 2027)
IICS4all 2027 supports investigators conducting inclusive multinational clinical trials to compare existing interventions or repurpose off-patent drugs across four chronic disease areas to address patient needs.
Browse similar grants
Funder: European Commission
Due Dates: January 14, 2027, 12:00 CET (Pre-proposal) | June 14, 2027, 12:00 CEST (Full proposal, by invitation)
Funding Amounts: EUR 29,573,700 total funding; maximum duration 48 months
Summary: Supports inclusive multinational phase III clinical trials comparing existing interventions or repurposing off-patent drugs across four chronic disease areas.
Key Information: Consortia must involve eligible partners from 3–5 participating countries; each Principal Investigator may join only one pre-proposal.
Description
IICS4all 2027 is run by ERA4Health, a European Commission-funded partnership fostering a European Research Area for health research. It supports pragmatic, phase III, randomised controlled, multinational interventional Investigator-Initiated Clinical Studies with high public relevance. Studies must address comparative effectiveness and/or repurposing of off-patent drugs in cardiovascular diseases, metabolic disorders, autoimmune diseases or non-communicable respiratory diseases. These four areas have equal importance.
Projects may address multiple eligible conditions and related comorbidities, and may use existing cohorts, including Trials within Cohorts. Inclusivity and diversity are central priorities, with sex/gender-sensitive, age-specific and other diversity-related considerations incorporated where relevant. The call also emphasises Responsible Research and Innovation, patient involvement and relevance to patient needs.
